Using an experimental drug, researchers were able to suppress a mutated amyotrophic lateral sclerosis (ALS) gene. Studies in mice demonstrate that the therapy could show promise in treating rare, ...
Using an experimental drug, researchers were able to suppress a mutated amyotrophic lateral sclerosis (ALS) gene. Studies in mice demonstrate that the therapy could show promise in treating rare, ...
While filaments of either tau or TDP-43 underlie 90 percent of frontotemporal dementia cases, the proteopathic culprits behind the remaining 10 percent have eluded researchers. Fused in sarcoma (FUS) ...
As neurologists and neurobiologists gathered for the Third International Research Workshop on Frontotemporal Dementia in ALS, 21-25 June in London, Ontario, Canada, the big buzz was all about Fused in ...
Typically, the goal of ALS treatments is to slow the disease or halt progression. But new data from the antisense oligonucleotide (ASO) jacifusen for FUS-ALS show that two patients went beyond the ...
NEW YORK, NY (Jan. 24, 2022)--An experimental drug, first tried at Columbia University Irving Medical Center as a last-ditch effort to help a 25-year-old woman with juvenile ALS, is now being tested ...
When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he's unwaveringly honest. "Patients always ask me, 'What can I hope to get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback